Federal Contractor Profile
Melinta Therapeutics, LLC
Federal contracting record: $65M obligated across 7 awards from 2 agencies, FY 2016–2026.
Company Profile
Parent UEI (Unique Entity Identifier)
H8K6F2A4KD49
CAGE Code
4D2L7
Registered Entities (UEIs)
3 under this organization
Address
2530 MERIDIAN PKWY STE 300, DURHAM, NC, 27713
First Federal Award
Nov 10, 2015
Most Recent Award
Sep 18, 2026
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- Department of Health and Human Services$65M
100.0% of total obligations
- Department of Veterans Affairs$0
0.0% of total obligations
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Sep 25, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN | $8.6M |
| Sep 12, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN | $13M |
| Sep 5, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN | $4.6M |
| May 13, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN | $1.0M |
| Jul 6, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN | $21M |
| Sep 23, 2016 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | CEMPRA - SOLITHROMYCIN (CEM-101) FOR CIVILIAN USE AND BROAD BIOTERROR THREAT MEDICAL COUNTERMEASURES. | $8.0M |
| Feb 23, 2016 | Department of Health and Human ServicesOFF ASST SEC ADM AND MGMT | 541711 | CEMPRA - SOLITHROMYCIN (CEM-101) FOR CIVILIAN USE AND BROAD BIOTERROR THREAT MEDICAL COUNTERMEASURES. | $26M |
Want to win work like Melinta Therapeutics, LLC?
Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.